Effect of <i>Momordica charantia</i> Administration on Anthropometric Measures and Metabolic Profile in Patients with Obesity: A Pilot Clinical Trial

Cortez-Navarrete, Marisol; Villar, Miriam Méndez-del; Martı́nez-Abundis, Esperanza; López-Murillo, Luis D; Escobedo-Gutiérrez, Miriam de J.; Rosales-Rivera, Lizet Y; Pérez-Rubio, Karina G.

doi:10.1089/jmf.2021.0164

Cited by 3 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Random sequence generation was described in six studies ( 33 , 67 – 70 , 72 ); however, the measures taken to ensure allocation concealment were given in only one trial ( 67 ). Performance and detection biases were unclear in five studies ( 33 , 68 – 71 ) because the authors of these studies failed to report whether the intervention and the comparator were identical in size, shape, color, and odor; and it remained unclear whether the outcomes were assessed in a blinded manner or not.…”

Section: Resultsmentioning

confidence: 99%

“…Performance and detection biases were unclear in five studies ( 33 , 68 – 71 ) because the authors of these studies failed to report whether the intervention and the comparator were identical in size, shape, color, and odor; and it remained unclear whether the outcomes were assessed in a blinded manner or not. The study of Cortez-Navarrante ( 72 ) was judged to have low risk of performance and detection biases, because based on their article nor the patients neither the investigators were aware of the assigned treatment. Dans et al stated that the treatment and the placebo capsules were identical, and the patients, the investigators, and the statistician were unaware of the treatments received until the end of the statistical analysis.…”

Section: Resultsmentioning

confidence: 99%

“…The assessment of the VLDL data is not conclusive, as data from only two studies were available ( 68 , 72 ).…”

Section: Resultsmentioning

confidence: 99%

“…Based on data from four trials ( 33 , 67 , 68 , 72 ), M. charantia administration exerted no significant effects on liver enzymes (ALT, AST) and creatinine levels (Supplementary Figure S6) compared to placebo, however confidence intervals were sometimes wide to draw reliable safety conclusions (i.e., power was low).…”

Section: Resultsmentioning

confidence: 99%

“…In this review and meta-analysis, we have systematically evaluated the existing evidence on the potential efficacy of bitter melon in the treatment of metabolic syndrome, based on randomized, parallel-group, placebo-controlled trials. All the included trials, except the studies of Cortez-Navarrete ( 68 , 72 ) were carried out in different Asian countries. Based on the nine trials included in this study, our findings show that M. charantia mono herbal preparations do not have a significant overall positive influence on blood glucose levels and other cardiovascular risk factors associated with metabolic syndrome.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

The metabolic effect of Momordica charantia cannot be determined based on the available clinical evidence: a systematic review and meta-analysis of randomized clinical trials

Laczkó-Zöld,

Csupor-Löffler,

Kolcsár

et al. 2024

Front. Nutr.

View full text Add to dashboard Cite

Several studies have shown that Momordica charantia L. (Cucurbitaceae, bitter melon) has beneficial effects on metabolic syndrome (MetS) parameters and exerts antidiabetic, anti-hyperlipidemic, and anti-obesity activities. Since the findings of these studies are contradictory, the goal of this systematic review and meta-analysis was to assess the efficacy of bitter melon in the treatment of metabolic syndrome, with special emphasis on the anti-diabetic effect. Embase, Cochrane, PubMed, and Web of Science databases were searched for randomized controlled human trials (RCTs). The meta-analysis was reported according to the PRISMA statement. The primary outcomes of the review are body weight, BMI, fasting blood glucose, glycated hemoglobin A1c, systolic blood pressure, diastolic blood pressure, serum triglyceride, HDL, LDL, and total cholesterol levels. Nine studies were included in the meta-analysis with 414 patients in total and 4–16 weeks of follow-up. In case of the meta-analysis of change scores, no significant effect could be observed for bitter melon treatment over placebo on fasting blood glucose level (MD = −0.03; 95% CI: −0.38 to 0.31; I2 = 34%), HbA1c level (MD = −0.12; 95% CI: −0.35 to 0.11; I2 = 56%), HDL (MD = −0.04; 95% CI: −0.17 to 0.09; I2 = 66%), LDL (MD = −0.10; 95% CI: −0.28 to 0.08; I2 = 37%), total cholesterol (MD = −0.04; 95% CI: −0.17 to 0.09; I2 = 66%,), body weight (MD = −1.00; 95% CI: −2.59–0.59; I2 = 97%), BMI (MD = −0.42; 95% CI: −0.99–0.14; I2 = 95%), systolic blood pressure (MD = 1.01; 95% CI: −1.07–3.09; I2 = 0%) and diastolic blood pressure levels (MD = 0.24; 95% CI: −1.04–1.53; I2 = 0%). Momordica treatment was not associated with a notable change in ALT, AST, and creatinine levels compared to the placebo, which supports the safety of this plant. However, the power was overall low and the meta-analyzed studies were also too short to reliably detect long-term metabolic effects. This highlights the need for additional research into this plant in carefully planned clinical trials of longer duration.

show abstract